Development Programs

Connecting Surgical Performance With Biological Design.

The Synthetic Coronary Conduit Program brings mechanical engineering, surgical usability, and targeted biomimetic function into a single development strategy for CABG.

The Clinical Context

Why Develop Another Coronary Conduit?

Autologous grafts are living arteries or veins taken from the patient. They remain the foundation of CABG, with the left internal thoracic artery an established choice for the left anterior descending coronary artery.[1]

The challenge is not that native grafts are inherently inadequate. Surgeons must work within each patient’s available vessels, harvesting requirements, and expected graft durability.

Availability And Suitability

Previous harvesting, poor vein quality, vascular disease, and patient-specific contraindications can restrict conduit choices.[2]

Harvest-Related Burden

Obtaining a leg vein or arm artery creates an additional operative task and donor site. Minimally invasive harvesting reduces this burden but does not remove it.[3]

Long-Term Graft Function

Vein grafts can narrow or occlude over time. Outcomes depend on conduit selection, surgical handling, target-vessel characteristics, and postoperative treatment.[4]

Preparation, Recovery, And Resources

The Work Behind A Harvested Conduit.

Conduit preparation requires careful tissue handling. Published guidance addresses these steps, while technique, training, and clinical workflow remain important.[4]

Preparation And Tissue Integrity

A UK survey published in 2023 collected 120 responses from all 35 adult cardiac units and identified eight preservation-fluid approaches.[5] Harvesting and preparation can expose vessels to mechanical or thermal injury.[4] A small imaging study also linked harvester experience with differences in conduit injury.[6]

Donor-Site Recovery

Endoscopic harvesting offers wound-healing advantages over open harvest, but hematoma, seroma, cellulitis, and wound separation remain documented complications.[7] Harvest-site infection can require antibiotics and surgical revision.[8]

Resources And Care

Harvesting requires dedicated equipment, trained personnel, and operative work. Wound complications can add hospital treatment, outpatient wound care, and readmission.[9][10]

Selected published evidence illustrates the care burden. Results depend on the population, technique, and healthcare setting.

Readmission After Secondary Infection

In a prospective, 2,174-patient U.S. and Canadian CABG cohort, readmission within 65 days occurred in 34% of patients with secondary leg or groin surgical-site infection, versus 17% without.[9]

Enrolled in 2010; published in 2018. The endpoint included vein-harvest and perfusion-cannulation sites, so this is not an isolated harvest-site effect.

Wound Care Has A Measurable Cost

A 2016 UK matched pilot study of high-risk patients reported total leg-wound treatment costs of £78,036 across 50 open-harvest patients and £2,758 across 50 endoscopic-harvest patients.[10]

Small historical cohort; GBP as reported, with price year unspecified. These are group treatment costs, not whole-CABG costs, current average prices, or projected device savings.

A larger U.S. randomized economic analysis found no significant difference in index-procedure or follow-up costs between endoscopic and open harvesting.[11]

What We Are Developing

We are developing an off-the-shelf, surgeon-tailorable coronary conduit for routing, trimming, and suturing while preserving the structural and biological functions specified in its design. We consider mechanical design and biological activity together, rather than treating either as a stand-alone solution.

Three Connected Design Priorities

Mechanical Performance

Our evaluation plan examines scaffold behavior under conditions relevant to coronary use and identifies the limits that require further development.

Surgical Handling

The handling evaluation plan examines manipulation and suturing against the practical demands of CABG.

Targeted Biomimetic Function

Our development program integrates biological functions directed at relevant graft failure mechanisms, with planned evaluation of compatibility with the conduit and surgical use.

Designed Around The Realities of CABG

Why This Matters

Time

Potential to reduce preparation and harvesting work in cases where a ready-to-use conduit replaces a harvested vessel.

Resource Use And Cost

Potential to lower harvest-related resource use and complication burden. Economic evaluation must account for the device cost and the full episode of care.

Patient Care

Potential to expand graft options for patients with limited suitable vessels and reduce donor-site burden when a harvest is avoided.

These are development goals, not demonstrated clinical or economic benefits. ZoIvian is pre-prototype; safety, performance, and value require validation.

Saphenous vein harvesting can occur alongside internal mammary artery dissection during CABG.[12] Less harvesting should therefore not be equated with a shorter operation; any effect on procedure time requires validation.

How The Program Advances

Stage A — Establish The Baseline

The initial work package defines fabrication and bench evaluation to establish practical feasibility and a scaffold baseline.

Stage B — Evaluate Biological Functions

The biological evaluation plan compares selected biomimetic approaches with the baseline against defined objectives.

Stage C — Assess Integrated Performance

The integrated evaluation plan examines structural behavior, surgical handling, and biological functions together. Progression depends on the evidence generated at each stage.

Evidence-Informed, With Clear Boundaries

Published scientific research informs our starting platform. Our coronary adaptation and integrated biomimetic design require their own evaluation, with company-specific performance established through staged testing.

ZoIvian-specific mechanical, biological, and clinical performance must be established through the development program.
Discuss scientific or technical collaboration

Sources & References

These references support the clinical context, not ZoIvian product performance.

  1. Lawton JS, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. J Am Coll Cardiol. 2022;79(2):e21–e129. Section 12.2: bypass conduits in patients undergoing CABG. Read source. Return to text
  2. Leonardi S, et al. Composition, structure, and function of heart teams. Joint ACVC/EAPCI/EACTS/EACTA position paper. Eur J Cardiothorac Surg. 2021;59:522–531. Conduit-selection section. Read source. Return to text
  3. Zenati MA, et al. Randomized Trial of Endoscopic or Open Vein-Graft Harvesting for Coronary-Artery Bypass. N Engl J Med. 2019;380:132–141. REGROUP trial. Read source. Return to text
  4. Sandner S, et al. Intra-operative and post-operative management of conduits for coronary artery bypass grafting. ESC/EACTS clinical consensus statement. Eur J Cardiothorac Surg. 2024;66(6):ezae400. Read source. Return to text
  5. Layton GR, et al. The Role of Preservation Solutions upon Saphenous Vein Endothelial Integrity and Function: Systematic Review and UK Practice Survey. Cells. 2023;12(5):815. Descriptive practice survey, not an adherence audit. Read source. Return to text
  6. Desai P, et al. Impact of the learning curve for endoscopic vein harvest on conduit quality and early graft patency. Ann Thorac Surg. 2011;91(5):1385–1391. Small nonrandomized imaging study. Read source. Return to text
  7. Bitondo JM, et al. Endoscopic versus open saphenous vein harvest: a comparison of postoperative wound complications. Ann Thorac Surg. 2002;73(2):523–528. Prospective nonrandomized comparison. Read source. Return to text
  8. Unosson H, et al. Risk factors for infection at the saphenous vein harvest site after coronary artery bypass grafting surgery: a retrospective cohort study. J Cardiothorac Surg. 2024;19:310. Single-center Swedish open-harvest cohort, 2009–2018; not an endoscopic-harvest cohort. Read source. Return to text
  9. Gulack BC, et al. Secondary Surgical Site Infection after Coronary Artery Bypass Grafting: A Multi-Institutional Prospective Cohort Study. J Thorac Cardiovasc Surg. 2018;155(4):1555–1562.e1. Secondary leg/groin infections included harvest and cannulation sites. Read source. Return to text
  10. Luckraz H, et al. Endoscopic vein harvest in patients at high risk for leg wound complications: A cost-benefit analysis of an initial experience. Am J Infect Control. 2016;44(12):1606–1610. UK matched pilot, 50 patients per group; historical treatment costs in GBP. Read source. Return to text
  11. Wagner TH, et al. Costs of Endoscopic vs Open Vein Harvesting for Coronary Artery Bypass Grafting: A Secondary Analysis of the REGROUP Trial. JAMA Netw Open. 2022;5(6):e2217686. Randomized 1,150-patient U.S. VA trial; costs standardized to 2020 USD. Read source. Return to text
  12. Funston W, et al. A human model of bilateral pulmonary vein sampling to assess the effects of one-lung ventilation on neutrophil function. PLoS ONE. 2022;17(7):e0271958. Surgical-procedures methods document concurrent vein harvesting and internal mammary artery dissection. Read source. Return to text